COMPARISON OF A 2ND-GENERATION COMBINATION CHEMOTHERAPEUTIC REGIMEN (M-BACOD) WITH A STANDARD REGIMEN (CHOP) FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA
COMPARISON OF A 2ND-GENERATION COMBINATION CHEMOTHERAPEUTIC REGIMEN (M-BACOD) WITH A STANDARD REGIMEN (CHOP) FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA
复制标题
DOI：
10.1056/nejm199211053271903
复制
发表时间：
1992-11-05
影响因子：
158.5
通讯作者：
OCONNELL, M
中科院分区：
文献类型：
--
作者：
GORDON, LI;HARRINGTON, D;OCONNELL, M
背景资料。1984年，东方合作肿瘤学小组开始了一项对晚期(III或IV期)弥漫性混合或弥漫性大细胞淋巴瘤患者的随机对照临床试验，以确定患者接受包含环磷酰胺、阿霉素、长春新碱和强的松(CHOP)的化疗方案与包含博莱霉素、阿霉素、环磷酰胺、长春新碱、地塞米松、甲氨蝶呤和亚叶酸钙(m-BACOD)的化疗方案是否有不同的完全缓解率、存活率和毒性。从1984年7月至1988年1月，392名患者入选，其中325名(83%)符合分析并能够进行评估。疾病的程度是根据标准的分期技术来定义的，包括88%的患者的双侧骨核活检。随机分组按年龄分层(
Background. In 1984, the Eastern Cooperative Oncology Group began a randomized controlled clinical trial of patients with advanced (stage III or IV) diffuse mixed or diffuse large-cell lymphoma to determine whether complete-remission rates, survival, and toxicity differed when patients were treated with a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as compared with a regimen containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD).Methods. From July 1984 through January 1988, 392 patients were enrolled, 325 of whom (83 percent) were eligible for the analysis and capable of being evaluated. The extent of disease was defined according to standard staging techniques, including bilateral bone-core biopsies in 88 percent of patients. Randomization was stratified according to age (